(DARE) Daré Bioscience, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(DARE) Daré Bioscience, Inc. Complete Analysis Pack
Unlock Strategic Clarity
This Daré Bioscience, Inc. 4P's Marketing Mix Analysis explains the company’s products, their uses, pricing, distribution channels, and promotional tactics in a concise, business-ready format; the page includes a real preview/sample of the analysis so you can evaluate style and substance before buying. Purchase the full version to receive the complete, ready-to-use report.
Product
XACIATO prescription gel
XACIATO is Daré Bioscience, Inc.'s first commercial product: a single-dose clindamycin phosphate vaginal gel for bacterial vaginosis in females aged 12 and older, approved by the U.S. Food and Drug Administration in 2021.
In the Product part of the 4P's mix, its one-dose format and prescription use help target a common condition that affects about 21 million U.S. women ages 14 to 49.
That clear use case gives Daré a focused launch asset with clinical and commercial value.
Ovaprene monthly contraceptive
Ovaprene is Daré Bioscience, Inc.'s monthly, hormone-free vaginal contraceptive in advanced clinical development. It is aimed at women who want reversible, non-hormonal birth control, which keeps it in a large addressable market where many users still want options beyond daily pills or long-acting devices. Its monthly dosing and non-hormonal design are key product differentiators.
Sildenafil Cream female sexual health
Sildenafil Cream is a topical sildenafil product for vulvar and vaginal use, aimed at female sexual arousal disorder. Daré Bioscience is targeting a large need area: female sexual dysfunction affects about 40% of women in some studies, while approved U.S. options remain limited. As a prescription-led niche product, its value sits in a high-unmet-need market rather than current sales.
DARE-HRT1 intravaginal ring
DARE-HRT1 is Daré Bioscience, Inc.'s Phase 1 intravaginal ring for hormone therapy, built to deliver bio-identical estradiol and progesterone in one device. Its main use is vasomotor symptom control, the hot flashes and night sweats that affect up to 80% of women during menopause.
As an early-stage program, it has no approved sales yet, so its value sits in clinical proof, dosing convenience, and monthly ring-based delivery. The two-hormone design aims to simplify treatment versus separate products.
- Phase 1 clinical stage
- Two bio-identical hormones
- Targets vasomotor symptoms
- Intravaginal ring delivery
Pipeline breadth in women’s health
Daré Bioscience, Inc.’s women’s health pipeline spans 7 named programs: DARE-VVA1, DARE-FRT1, DARE-PTB1, DARE-LARC1, ADARE-204, ADARE-214, and DARE-RH1. The mix covers contraception, fertility, preterm birth prevention, and vaginal health, with work running from Phase 1 to pre-clinical stages. That breadth gives Company Name multiple shots at clinical and commercial value, not one single bet.
7 pipeline programs
4 core women’s health areas
Stages: Phase 1 to pre-clinical
Daré Bioscience’s Pipeline Targets Big Unmet Women’s Health Needs
Daré Bioscience, Inc.'s product mix is led by XACIATO, a 2021 FDA-approved single-dose BV gel, plus Ovaprene, a monthly non-hormonal contraceptive in advanced development. Sildenafil Cream and DARE-HRT1 target large unmet needs in female sexual health and menopause, while 7 named pipeline programs widen future optionality.
| Asset | Stage | Key value |
|---|---|---|
| XACIATO | Approved | Single-dose BV |
| Ovaprene | Adv. dev. | Monthly, non-hormonal |
What is included in the product
Detailed Word Document
Concise, company-specific 4P analysis of Daré Bioscience, Inc.’s product, pricing, distribution, and promotion strategy.
Editable Excel File
Condenses Daré Bioscience’s 4Ps into a quick, clear snapshot that simplifies analysis and speeds decision-making.
Reference Sources
Consolidates primary industry reports, FDA documents, clinical trial data, and financial filings to let investors verify Daré Bioscience claims quickly.
Place
United States women’s health market
Daré Bioscience, Inc. operates in the United States, where women make up about 51% of the population and the U.S. women’s health market supports broad demand in contraception, fertility, and sexual health.
The company targets U.S. patients and healthcare providers, so its place strategy depends on national clinic, pharmacy, and telehealth access. This fits a market where 62 million U.S. women are in their reproductive years, making reach and provider trust key.
San Diego, California headquarters
Daré Bioscience keeps its corporate headquarters in San Diego, California, and this is its main operating base. Founded in 2015, the company runs corporate and development work from this location, keeping key decisions close to its biotech network. The San Diego hub supports day-to-day management, strategy, and product development.
Organon commercialization channel
Daré Bioscience, Inc. uses a partner-led path for XACIATO through its license to Organon & Co. and Organon International GmbH, so market access and commercialization sit with Organon, not Daré. Organon reported 2025 net sales of about $6.4 billion, giving the product a much larger sales reach than Daré could build alone. That setup is the core commercialization channel.
Prescription access route
XACIATO is a prescription-only product, so Daré Bioscience, Inc. depends on healthcare providers to write the order and pharmacies to fill it. That makes Place a medical channel issue, not a retail shelf issue, and access hinges on prescriber awareness and pharmacy stock. Since XACIATO is the company’s FDA-approved vaginal gel for bacterial vaginosis, the route stays tightly tied to office-based diagnosis and dispensing.
- Provider write-in drives demand.
- Pharmacy fulfillment closes access.
- Channel is prescription-only.
Clinical development footprint
Daré Bioscience’s clinical development footprint is built around multiple programs moving through advanced clinical, Phase 1, and pre-clinical work, so trial-site access and execution quality matter more than scale. Its model is still development-first, with broad commercialization deferred until data de-risks the pipeline.
Multi-stage pipeline, not mass rollout.
Depends on trial sites and study execution.
Commercial expansion comes after proof.
Daré Bioscience’s U.S. Reach Runs Through Partner-Led Prescription Access
Daré Bioscience, Inc. keeps Place centered on the U.S., with San Diego as its operating base and national access depending on clinics, pharmacies, and telehealth. XACIATO is sold through Organon, so Daré relies on a partner-led channel, not direct retail reach. Prescription access keeps prescribers and pharmacy stocking central.
| Place factor | Key data |
|---|---|
| Base | San Diego, California |
| Market | United States |
| XACIATO channel | Organon-led |
| Access | Prescription-only |
Preview the Actual Deliverable
Daré Bioscience, Inc. Reference Sources
The preview shown here is the exact, full Daré Bioscience 4P's Marketing Mix analysis you’ll receive instantly after purchase—no samples or surprises.
This document is ready-made and actionable, covering product, price, place, and promotion insights tailored to Daré Bioscience.
Download the same comprehensive, editable file immediately after checkout and use it straightaway for strategy or investment decisions.
Promotion
Organon-led product launch
Daré Bioscience, Inc. uses a licensing model for XACIATO, with Organon leading commercialization and launch work. That lets Daré avoid building a standalone sales force and lowers fixed promo costs; Daré can stay asset-light while Organon handles market reach. XACIATO was FDA-approved in December 2022, and the partner-led launch fits Daré’s capital-light strategy.
Women’s health positioning
Daré Bioscience positions itself as a women’s health company, and its pipeline spans 4 clear areas: contraception, fertility, sexual health, and vaginal health. That single-category message helps make a narrow biotech story easier to understand and sell. In a market where women’s health remains underfunded, this focus gives Daré a sharper promo angle than a broad, unfocused pipeline.
Prescription indication messaging
XACIATO’s prescription-only status keeps the message physician-facing, with promotion centered on bacterial vaginosis treatment. The label also targets patients aged 12 years and older, which gives Daré Bioscience, Inc. a clear age-based message. That narrow Rx position helps focus detail on the 1-condition use case and the approved patient group.
Pipeline progress updates
Daré Bioscience promotes itself through clinical milestones, and its pipeline updates keep Ovaprene, Sildenafil Cream, and DARE-HRT1 in front of investors and partners. The message is simple: progress in several programs shows optionality, not just one shot on goal. In 2025, that breadth remained a key visibility driver as each update can shift partner interest and valuation.
Milestones drive investor visibility.
Three named programs widen the story.
Pipeline breadth supports partner talks.
Corporate and partner communications
Daré Bioscience, Inc. is a clinical-stage biopharmaceutical Company, so promotion depends on scientific, clinical, and business communications, not mass-market ads. Its public updates on development programs and licensing deals are the main way it explains value, risk, and progress to investors, partners, and clinicians.
- Focuses on trial data and milestones
- Uses disclosures to support licensing
- Targets investors and partners first
- Promotion follows regulatory limits
Daré Keeps XACIATO Promotion Lean with Partner-Led Marketing
Daré Bioscience, Inc. keeps Promotion lean by using Organon to market XACIATO, so it avoids a costly field force and stays asset-light. The message is narrow: bacterial vaginosis, prescription-only use, and patients 12 years and older. Broader promotion comes from pipeline news on Ovaprene, Sildenafil Cream, and DARE-HRT1.
| Item | Promo angle |
|---|---|
| XACIATO | Partner-led Rx launch |
| Target | Patients 12+ |
| Pipeline | Milestone-led visibility |
Price
XACIATO price not disclosed
No pricing information for XACIATO is disclosed in the supplied facts. As a prescription-only, commercially licensed product, the patient cost will depend on launch terms, formulary status, and payer coverage. Daré Bioscience, Inc. has not provided a public list price here, so any real-world price would likely vary by channel and insurance access.
Ovaprene price not available
Ovaprene has no market price because Daré Bioscience, Inc. is still developing it and has not launched it commercially. Pricing is typically set only after FDA approval, payer review, and launch, so any current price would be speculative. In Daré Bioscience, Inc.’s 2025 disclosures, Ovaprene remained a clinical-stage program, with no product sales tied to it yet.
Sildenafil Cream price not available
Sildenafil Cream remains in development, so Daré Bioscience, Inc. has not disclosed a list price yet. The supplied material also gives no reimbursement terms or payer coverage, so pricing cannot be benchmarked today. Any price point will stay unpublicized until later-stage data and commercialization plans are set.
Pipeline programs unpriced
Daré Bioscience, Inc. keeps DARE-HRT1, DARE-VVA1, DARE-FRT1, DARE-PTB1, DARE-LARC1, ADARE-204, ADARE-214, and DARE-RH1 unpriced because they are still pipeline assets, not commercial products. No list price or net price is disclosed yet, so any future pricing will hinge on clinical readouts, FDA or other regulatory outcomes, and eventual market access. Until then, their value is tied to development progress, not sales.
No commercial launch yet
No pricing disclosed
Price depends on approval and adoption
Discounts and payment terms not disclosed
Daré Bioscience, Inc. does not disclose discounts, rebates, financing, or credit terms in the supplied material, so there is no public price schedule to assess here. As a clinical-stage company, its focus is on development and regulatory progress, not full commercial pricing transparency.
That means the "Price" element of the 4P mix is currently limited to what is not stated. No public figures are given for unit price, payer terms, or volume-based concessions in this prompt.
- Discounts: not disclosed
- Rebates: not disclosed
- Financing: not disclosed
- Credit terms: not disclosed
Daré Bioscience Pricing: Mostly Undisclosed, with Future Value Still Unpriced
Price is mostly undisclosed for Daré Bioscience, Inc. XACIATO has no public list price here, while Ovaprene, Sildenafil Cream, and pipeline assets still have no commercial price because they are not launched. Any future price will depend on FDA approval, payer coverage, and channel terms.
| Asset | Price |
|---|---|
| XACIATO | Not disclosed |
| Ovaprene | No market price |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.